Pricing Strategies; Reimbursement
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Amid media reports of Teva walking away from settlement negotiations with the US Department of Justice over generic price-fixing allegations, the Israeli company is officially maintaining silence over the matter.
Erythromycin and paracetamol were among the products with the steepest price rises in the UK in April, as the coronavirus pandemic continued to make its effects felt in the generics market.
Gedeon Richter has high ambitions for biosimilars, recently penning a deal to bring in a tocilizumab biosimilar that is currently under development. During its first-quarter earnings call, the Hungarian company’s CEO gave his current thinking on how payers may treat biosimilars amidst the COVID-19 pandemic.
Apotex has agreed to pay a $24.1m fine and enter into a deferred prosecution agreement to resolve US price-fixing claims over the cholesterol-lowering drug pravastatin.
Belgian body Medaxes is content with the latest pharmaceutical pricing legislation in the country, which cuts generics and biosimilars prices but also exempts such drugs from pharmaceutical clawback taxes.
The BGMA has emphasized the importance of prioritizing transport of medicines across borders, at the same time as it has praised decisions by the UK competition authority and European Commission to relax rules on co-ordinating to facilitate the supply of medicines.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.